SHARE

GSK reports strong second quarter

Q2 constant currency sales lifted by 6% to £8bn, which has led to GSK revising its 2025 financial guidance. It now expects results towards the top end of its 3-5% bracket. Total operating profit rose 33% and speciality medicines sales lifted 15%.

Certification Note

Certified B Corporation” is a trademark licensed by B Lab, a private non-profit organization, to companies like ours that have successfully completed the B Impact Assessment (“BIA”) and therefore meet the requirements set by B Lab for social and environmental performance, accountability, and transparency. It is specified that B Lab is not a conformity assessment body as defined by Regulation (EU) No 765/2008, nor is it a national, European, or international standardization body as per Regulation (EU) No 1025/2012. The criteria of the BIA are distinct and independent from the harmonized standards resulting from ISO norms or other standardization bodies, and they are not ratified by national or European public institutions.